Skip to content
value.today

Marinus Pharmaceuticals Inc.

Total raised
$73 M
4 rounds on record
Latest round
$1 M
Mar 2022
First round on record
Apr 2009
Today
Private
No later event on record

Funding rounds

4 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Marinus Pharmaceuticals Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Mar 2022$1 MNo. 4Under $2 million

Marinus Pharmaceuticals Inc.: Raise no. 4, Mar 2022

Investors in this round

1 investor had bought by the notice of Apr 4, 2022: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 8 investors are named for Marinus Pharmaceuticals Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$1 M of $1 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Joseph E. Hulihan, M.D. · Executive Officer · Chief Medical Officer
  • Martha E. Manning, Esq. · Executive Officer · Vice President, General Counsel, and Secretary
  • Scott Braunstein, M.D. · Executive Officer, Director · Chief Executive Officer and Director
  • Steven E. Pfanstiel · Executive Officer · Chief Financial Officer
  • Charles E. Austin · Director
  • Elan R. Ezickson · Director
  • Michael R. Dougherty · Director
  • Nicole E. Vitullo · Director · Director, Chairman of the Board
  • Santiago E. Arroyo, M.D., Ph.D. · Director
  • Saraswathy M. Nochur, Ph.D. · Director
  • Seth H.Z. Fischer · Director
  • Tim M. Mayleben · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Steven E. Pfanstiel, Chief Financial Officer. Source: SEC Form D, newest notice filed Apr 4, 2022. Read the notice at the SEC.

equitySEC
Dec 2019$30 MNo. 3$10 to $50 million

Marinus Pharmaceuticals Inc.: Raise no. 3, Dec 2019

Investors in this round

4 investors had bought by the notice of Dec 19, 2019: 4 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 8 investors are named for Marinus Pharmaceuticals Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$30 M of $30 M offered
Smallest investment taken
$4,625,000
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$1,800,000
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Edward F. Smith · Executive Officer
  • Joe F. Hulihan, MD · Executive Officer
  • Scott Braunstein, MD · Executive Officer, Director
  • Elan M. Ezickson · Director
  • Enrique J. Carrazana, MD · Director
  • Michael R. Dougherty · Director
  • Nicole M. Vitullo · Director
  • Seth H.Z. Fischer · Director
  • Tim M. Mayleben · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Oppenheimer & Co., Inc (CRD 249) · New York, New YorkSold in all US states
  • Ladenburg Thalmann & Co. Inc. (CRD 505) · New York, New YorkSold in all US states
  • Craig-Hallum Capital Group LLC (CRD 121395) · Minneapolis, MinnesotaSold in all US states

Signed by Edward F. Smith, Vice President and Chief Financial Officer. Source: SEC Form D, newest notice filed Dec 19, 2019. Read the notice at the SEC.

equitySEC
Dec 2012$22 MNo. 2$10 to $50 million

Marinus Pharmaceuticals Inc.: Raise no. 2, Dec 2012

Investors in this round

7 investors had bought by the notice of Jul 9, 2013: 7 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 8 investors are named for Marinus Pharmaceuticals Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$22 M of $22 M offered; $1 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
$1,000,000 (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Christopher M. Cashman · Executive Officer, Director
  • Anand T. Mehra, M.D. · Director
  • Anton M. Gopka · Director
  • Harry M. Penner · Director
  • Harry T. Rein · Director
  • Nicole T. Vitullo · Director
  • Stephen M. Bloch, M.D. · Director
  • Timothy M. Mayleben · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “Offering includes cash proceeds and proceeds of indebtedness of the Issuer converted in the offering”

Signed by Christopher M. Cashman, Chief Executive Officer. Source: SEC Form D and 1 amendment, newest notice filed Jul 9, 2013. Read the notice at the SEC.

equitySEC
Apr 2009$20 MNo. 1$10 to $50 million

Marinus Pharmaceuticals Inc.: Raise no. 1, Apr 2009

Investors in this round

7 investors had bought by the notice of Apr 22, 2009: 7 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 8 investors are named for Marinus Pharmaceuticals Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$20 M (amount offered: indefinite)
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in De

People named in the notice

  • Alan Barber · Executive Officer · ACTING CHIEF FINANCIAL OFFICER AND ASSISTANT TREASURER
  • Cable Stuart · Executive Officer · ASSISTANT SECRETARY
  • John Krayacich · Executive Officer, Director · CHIEF EXECUTIVE OFFICER, PRESIDENT AND TREASURER
  • Kenneth Shaw · Executive Officer · VICE PRESIDENT, SECRETARY AND ASSISTANT TREASURER
  • Anand Mehra · Director
  • Harry H. Penner, Jr. · Director
  • Nicole Vitullo · Director
  • Stephen Bloch · Director · CHAIRMAN OF THE BOARD OF DIRECTORS
  • Timothy Mayleben · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by John Krayacich, Chief executive officer, president and treasurer. Source: SEC Form D, newest notice filed Apr 22, 2009. Read the notice at the SEC.

equity, optionsSEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Marinus Pharmaceuticals Inc. chose not to state its revenue in its newest notice of a funding round (Apr 2022).

    SEC Form D · Apr 2022

  • The industry group it chose in its notices: Pharmaceuticals.

    SEC Form D · Apr 2022

That is all the official record says: Marinus Pharmaceuticals Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: the address on record now leads to another company's site.

Investors#

8 named in official filings. Open an investor to see everything it has backed.

Investors in Marinus Pharmaceuticals Inc.
InvestorKindAmountRoundRoleSource
Canaan Partners VII LLCFund or asset managernot statednot statedHeld Series A, B and C preferred stock, 10% owner, director (Form 3, 2014)SEC Form 3
Canaan VII L.P.Fund or asset managernot statednot statedHeld Series A, B and C preferred stock, 10% owner, director (Form 3, 2014)SEC Form 3
Domain Partners VI, L.P.Fund or asset managernot statednot statedHeld Series A, B and C preferred stock, 10% owner (Form 3, 2014)SEC Form 3
DP VI Associates, L.P.Fund or asset managernot statednot statedHeld Series A, B and C preferred stock, 10% owner (Form 3, 2014)SEC Form 3
Sofinnova Management VI, L.L.C.Fund or asset managernot statednot statedHeld Series A, B and C preferred stock, 10% owner (Form 3, 2014)SEC Form 3
Sofinnova Venture Affiliates VI LPVenture capitalnot statednot statedHeld Series A, B and C preferred stock, 10% owner (Form 3, 2014)SEC Form 3
Sofinnova Venture Partners VI GmbH & Co. KGVenture capitalnot statednot statedHeld Series A, B and C preferred stock, 10% owner (Form 3, 2014)SEC Form 3
Sofinnova Venture Partners VI L.P.Venture capitalnot statednot statedHeld Series A, B and C preferred stock, 10% owner (Form 3, 2014)SEC Form 3

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 4 rounds above had up to 7 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Marinus Pharmaceuticals Inc.
NameRoleNamed in
Joseph E. Hulihan, M.D.Chief Medical OfficerApr 2022
Martha E. Manning, Esq.Vice President, General Counsel, and SecretaryApr 2022
Scott Braunstein, M.D.Chief Executive Officer and DirectorApr 2022
Steven E. PfanstielChief Financial OfficerApr 2022
Edward F. SmithExecutive officerDec 2019
Joe F. Hulihan, MDExecutive officerDec 2019
Scott Braunstein, MDExecutive officerDec 2019
Christopher M. CashmanExecutive officerJul 2013
Alan BarberACTING CHIEF FINANCIAL OFFICER AND ASSISTANT TREASURERApr 2009
Cable StuartASSISTANT SECRETARYApr 2009
John KrayacichCHIEF EXECUTIVE OFFICER, PRESIDENT AND TREASURERApr 2009
Kenneth ShawVICE PRESIDENT, SECRETARY AND ASSISTANT TREASURERApr 2009
Charles E. AustinDirectorApr 2022
Elan R. EzicksonDirectorApr 2022
Michael R. DoughertyDirectorApr 2022
Nicole E. VitulloDirector, Chairman of the BoardApr 2022
Santiago E. Arroyo, M.D., Ph.D.DirectorApr 2022
Saraswathy M. Nochur, Ph.D.DirectorApr 2022
Scott Braunstein, M.D.Chief Executive Officer and DirectorApr 2022
Seth H.Z. FischerDirectorApr 2022
Tim M. MaylebenDirectorApr 2022
Elan M. EzicksonDirectorDec 2019
Enrique J. Carrazana, MDDirectorDec 2019
Nicole M. VitulloDirectorDec 2019
Scott Braunstein, MDDirectorDec 2019
Anand T. Mehra, M.D.DirectorJul 2013
Anton M. GopkaDirectorJul 2013
Christopher M. CashmanDirectorJul 2013
Harry M. PennerDirectorJul 2013
Harry T. ReinDirectorJul 2013
Nicole T. VitulloDirectorJul 2013
Stephen M. Bloch, M.D.DirectorJul 2013
Timothy M. MaylebenDirectorJul 2013
Anand MehraDirectorApr 2009
Harry H. Penner, Jr.DirectorApr 2009
John KrayacichCHIEF EXECUTIVE OFFICER, PRESIDENT AND TREASURERApr 2009
Nicole VitulloDirectorApr 2009
Stephen BlochCHAIRMAN OF THE BOARD OF DIRECTORSApr 2009
Timothy MaylebenDirectorApr 2009

About

Company in Radnor, United States.